NLTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (19 12月 2023 @ 06:00):

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology...

Stats
本日の出来高	109 095
平均出来高	5 520.00
時価総額	8.20M
EPS	$0 ( 2024-03-19 )
次の収益日	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.284
ATR14	$0.878 (25.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Woods Robert Keith	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Palekar Rohan	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Noonberg Sarah B.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Freedland Cory S.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Baffi Robert	Buy	15 400	Stock Option (Right to Buy)

INSIDER POWER
75.00
Last 94 transactions
Buy: 7 989 742 \| Sell: 1 025 638

ボリューム相関

長: -0.32 (neutral)

短: -0.52 (weak negative)

Signal:(16.09) Neutral

Neoleukin Therapeutics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Neoleukin Therapeutics 相関 - 通貨/商品

-0.04
( neutral )

0.06
( neutral )

-0.14
( neutral )

0.10
( neutral )

-0.16
( neutral )

-0.18
( neutral )

Neoleukin Therapeutics 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.010

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.010

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.100

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.